Last update 29 Aug 2025
Taizhou Junshi Biomedical Technology Co., Ltd.

Taizhou Junshi Biomedical Technology Co., Ltd.

Dissolved
| Subsidiary Company|2014|Jiangsu Sheng, China

Overview

Related

29
Clinical Trials associated with Taizhou Junshi Biomedical Technology Co., Ltd.
CTR20200192
/ RecruitingPhase 3
特瑞普利单抗联合贝伐珠单抗对比索拉非尼一线治疗晚期肝细胞癌的安全性和有效性的随机、开放、多中心III期研究
[Translation] A randomized, open-label, multicenter phase III study on the safety and efficacy of toripalimab combined with bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma
CTR20201226
/ RecruitingPhase 3
特瑞普利单抗联合仑伐替尼对比仑伐替尼单药一线治疗晚期肝细胞癌前瞻性随机对照双盲多中心III期临床研究
[Translation] A prospective, randomized, controlled, double-blind, multicenter phase III clinical study of toripalimab combined with lenvatinib versus lenvatinib alone as the first-line treatment for advanced hepatocellular carcinoma
CTR20192179
/ RecruitingPhase 3
特瑞普利单抗联合含铂双药化疗用于可手术IIIA期非小细胞肺癌受试者的随机、双盲、安慰剂对照、多中心III期临床研究
[Translation] A randomized, double-blind, placebo-controlled, multicenter phase III clinical study of toripalimab combined with platinum-based doublet chemotherapy in patients with operable stage IIIA non-small cell lung cancer
100 Clinical Results associated with Taizhou Junshi Biomedical Technology Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Taizhou Junshi Biomedical Technology Co., Ltd.
Login to view more data
100 Deals associated with Taizhou Junshi Biomedical Technology Co., Ltd.
Login to view more data
100 Translational Medicine associated with Taizhou Junshi Biomedical Technology Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 01 Oct 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Other
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Toripalimab
 ( PD-1 )		Advanced Lung Non-Small Cell Carcinoma
More
Discontinued
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free